



## indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) • Website : [www.indoco.com](http://www.indoco.com)  
PHONES : (91-22) 3386 1000 / 3386 1250 • FAX : (91-22) 2652 3067 / 2652 3976 • CIN : L85190MH1947PLC005913

January 25, 2018

|                                                                                                                                                                                                       |                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>The Listing Department<br>National Stock Exchange of India<br>Limited<br>Exchange Plaza,<br>Bandra - Kurla Complex<br>Bandra (East)<br><u>Mumbai - 400 051</u><br><i>Stock Code : INDOCO-EQ</i> | To<br>The Listing Department<br>Bombay Stock Exchange Limited<br>Floor 25, P. J. Towers,<br>Dalal Street,<br><u>Mumbai - 400 001</u><br><i>Stock Code : 532612</i> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir,


Sub : Information to pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015  
(Listing Regulations)

Pursuant to Regulation 30(2) read with Schedule III Part A Para A(4)(h) of the Listing Regulations, enclosed is a press release, inter alia covering the unaudited financial results of the Company for the quarter 31.12.2017.

Kindly note the above.

Thanking you,

Yours faithfully,  
For Indoco Remedies Limited

  
Jayshankar Menon  
Company Secretary

## Indoco's Net Profit Q-o-Q grows at 29%

**Mumbai, January 25, 2018:** Indoco Remedies posted revenues of ₹ 274.2 crore during the third quarter of FY 2017-18, as against ₹ 272.2 crores, for the same quarter last year. The Company's Profit After Tax is at ₹ 22.7 crores as against ₹ 17.6 crores, for the same quarter last year.

**Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said,** "The third quarter saw progressive growth in the Indian Business. On the International Business front, Europe and Emerging Markets too showed encouraging sales trend. Operating margins improved with EBIDTA at 16 % of sales and growth in PAT at 29%, over same quarter last year".

For the quarter ended December'17, the financials are as under:

(₹ in Crores)

| Particulars                                | Oct'17-<br>December'17 | Oct'16-<br>December'16 |
|--------------------------------------------|------------------------|------------------------|
| Net Revenue                                | 274.2                  | 272.2                  |
| EBIDTA                                     | 43.2                   | 39.2                   |
| Profit After Tax                           | 22.7                   | 17.6                   |
| EPS (Face value ₹ 2/-)<br>(Not annualized) | 2.46                   | 1.91                   |

### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 165 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It

generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

**For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com)